Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study.

Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study. Lancet. 2021 07 24; 398(10297):314-324.

View in: PubMed

subject areas

Aged
B-Cell Maturation Antigen
Female
Humans
Immunotherapy, Adoptive
Male
Middle Aged
Multiple Myeloma
United States

authors with profiles

Andrzej Jakubowiak